HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $24 price target.
June 20, 2023 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Coherus BioSciences and maintains a $24 price target.
The reiterated Buy rating and maintained $24 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Coherus BioSciences. This news is directly related to the company and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100